Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist

被引：54

作者：

Grossman, J

Faiferman, I

Dubb, JW

Tompson, DJ

Busse, W

Bronsky, E

Montanaro, A

Southern, L

Tinkelman, D

机构：

[1] University of Arizona, Tucson, AZ

[2] SmithKline Beecham Pharmaceuticals, Collegeville, PA

[3] Frythe, SmithKline Pharmaceutical, Welwyn, Hertfordshire

[4] Univ. of Wisconsin Hosp. and Clinics, Madison, WI

[5] Intermountain Allergy Group, Salt Lake City, UT

[6] Allergy Clinic, Portland, OR

[7] Princeton Allerg. and Asthma Assoc., Princeton, NJ

[8] Atlanta Allergy and Immunology, Research Foundation, Atlanta, GA

[9] University of Arizona, Tucson, AZ 85719

来源：

JOURNAL OF ASTHMA | 1997年 / 34卷 / 04期

关键词：

asthma; clinical trial; leukotriene receptor antagonist; ONO-1078; pranlukast; SB205312;

D O I：

10.3109/02770909709067222

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Pranlukast (SB 205312; ONO-1078), a potent, orally active selective cysteinyl-leukotriene receptor antagonist (LTRA), was developed in Japan for the treatment of asthma. This article reports results of the initial U.S. clinical evaluation of pranlukast. The primary objective of this multicenter study was to evaluate the safety and tolerability of pranlukast administered at doses of 337.5 mg b.i.d. and 450 mg b.i.d. in 65 patients with mild to moderate asthma. Pranlukast, a novel LTRA, is safe and well tolerated at doses of 337.5 mg b.i.d. and 450 mg b.i.d. Pranlukast has demonstrated clinical activity in patients with asthma.

引用

页码：321 / 328

页数：8

共 17 条

[1]

BARNES NC, 1997, IN PRESS THORAX

[2] A SPECIFIC LTD4 LTE4-RECEPTOR ANTAGONIST IMPROVES PULMONARY-FUNCTION IN PATIENTS WITH MILD, CHRONIC ASTHMA [J].

CLOUD, ML ;

ENAS, GC ;

KEMP, J ;

PLATTSMILLS, T ;

ALTMAN, LC ;

TOWNLEY, R ;

TINKELMAN, D ;

KING, T ;

MIDDLETON, E ;

SHEFFER, AL ;

MCFADDEN, ER ;

FARLOW, DS .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 140 (05) :1336-1339

[3]

CRETICOS PS, 1984, NEW ENGL J MED, V310, P1625

[4] RELEASE OF LEUKOTRIENES, PROSTAGLANDINS, AND HISTAMINE INTO NASAL SECRETIONS OF ASPIRIN-SENSITIVE ASTHMATICS DURING REACTION TO ASPIRIN [J].

FERRERI, NR ;

HOWLAND, WC ;

STEVENSON, DD ;

SPIEGELBERG, HL .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (04) :847-854

[5] EFFECT OF A LEUKOTRIENE ANTAGONIST, ONO-1078, ON BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS WITH ASTHMA [J].

FUJIMURA, M ;

SAKAMOTO, S ;

KAMIO, Y ;

MATSUDA, T .

RESPIRATORY MEDICINE, 1993, 87 (02) :133-138

[6]

HENDERSON WR, 1994, ANN ALLERGY, V72, P272

[7] Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma - A randomized controlled trial [J].

Israel, E ;

Cohn, J ;

Dube, L ;

Drazen, JM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :931-936

[8]

KOHI F, 1990, ANN ALLERGY, V65, P228

[9] INVIVO PHARMACOLOGICAL PROFILE OF ONO-1078 - A POTENT, SELECTIVE AND ORALLY ACTIVE PEPTIDE LEUKOTRIENE (LT) ANTAGONIST [J].

NAKAGAWA, N ;

OBATA, T ;

KOBAYASHI, T ;

OKADA, Y ;

NAMBU, F ;

TERAWAKI, T ;

AISHITA, H .

JAPANESE JOURNAL OF PHARMACOLOGY, 1992, 60 (03) :217-225

[10]

OKUDA M, 1988, ANN ALLERGY, V60, P537

← 1 2 →